Elder Pharmaceuticals Limited - Fundamental Company Report Including Financial, Business, Recent Development, Industry Overview, Competitors and Key Risk Analysis
Elder Pharma is an Indian company which manufactures a wide range of pharmaceutical products through research and development. The USD160mn Indian Pharmaceutical major is also into the business of manufacturing and marketing of diverse products through licensing agreements with international pharmaceutical companies. The company’s in-licensing agreements include Angelini (Italy GEAI), Invacare (US), Astellas (Japan) and it has recently entered into another deal with the US based Basel Pharmaceuticals for an ophthalmological product with market size of ` 6.50bn. The company has in-licensing agreements for about 30 products. This is one of the highest in the industry. Sales of in-licensing products contribute about 12-13% to the topline of the company.
The company has a strong products portfolio. The famous brands of the company are Shelcal, Eldervit and Chymoral. These products are leaders in their respective segments. In view of its growing exposure in formulations and generics, the company has made a proactive backward integration into the manufacture of APIs with the objective to control quality at all stages, strengthen logistics management and reduce costs. This integration has helped the company extend its value chain in its formulations driven business model and emerge increasingly competitive.
In India, the company’s manufacturing facilities are located in Maharashtra and Uttaranchal. The plant in Patalganga (Maharashtra) and Dehradun (Uttaranchal) are in line with US-FDA requirements.
The company has a strong products portfolio. The famous brands of the company are Shelcal, Eldervit and Chymoral. These products are leaders in their respective segments. In view of its growing exposure in formulations and generics, the company has made a proactive backward integration into the manufacture of APIs with the objective to control quality at all stages, strengthen logistics management and reduce costs. This integration has helped the company extend its value chain in its formulations driven business model and emerge increasingly competitive.
In India, the company’s manufacturing facilities are located in Maharashtra and Uttaranchal. The plant in Patalganga (Maharashtra) and Dehradun (Uttaranchal) are in line with US-FDA requirements.
1. SYNOPSIS
2. FINANCIAL PERFORMANCE
3. RECENT DEVELOPMENTS
4. BUSINESS
5. INDUSTRIAL OVERVIEW
6. FINANCIALS (BOTH CONSOLIDATED AND STANDALONE RESULTS
7. OUT LOOK & CONCLUSION/ VALUATION
8. PEER COMPARISON
9. KEY RISKS
2. FINANCIAL PERFORMANCE
3. RECENT DEVELOPMENTS
4. BUSINESS
5. INDUSTRIAL OVERVIEW
6. FINANCIALS (BOTH CONSOLIDATED AND STANDALONE RESULTS
7. OUT LOOK & CONCLUSION/ VALUATION
8. PEER COMPARISON
9. KEY RISKS
